Company intelligence / Profile preview

Oscient Pharmaceuticals Corporation

Waltham, Massachusetts, United Statescience.com ↗

Ownership: Private
Employees: ~205
Development stage: Commercial

Overview

Oscient developed and commercialized specialty pharmaceuticals including the antibiotic Factive® and the lipid-lowering agent ANTARA®. Its lead pipeline candidate was Ramoplanin for CDAD, which reached Phase III. The company filed for bankruptcy in July 2009 after financial difficulties. Key assets were sold off to other companies.[1][2]

Therapeutic areas: Men's HealthCardiovascularInfectious Diseases
Modalities: small molecules (e.g., antibiotics, cardiovascular drugs)[1][2][3]
Industry: Biotech

Drug pipeline

1 asset

ramoplanin

Unknown

Partnerships

Vicuron Pharmaceuticals/Pfizer Inc. – licensing agreement for Ramoplanin development rights.[1]

Beyond the preview

Go deeper on Oscient Pharmaceuticals Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oscient Pharmaceuticals Corporation.

Explore the full profile